Latest News

Media Release – Kiwis with MS ‘light years’ behind Aussie patients in treatment access and quality of life – study.

September 14, 2021 | Advocacy, Media, Study, Uncategorised

Media Release: 14 September 2021 (For Immediate Release) A new trans-Tasman study has highlighted alarming health inequities between New Zealand patients living with multiple sclerosis (MS) and their Australian counterparts — adding fuel to the ongoing fight for Pharmac to […]


McDonald 2017 finally receives PTAC recognition

May 25, 2021 | Advocacy, Media

Still unfunded, but finally acknowledged, McDonald 2017 criteria for diagnosing Multiple Sclerosis (MS) is one step closer to being used in NZ for accessing treatment. The February 2021 minutes of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC) were released this month, recommending […]


Disease Modifying Treatment Special Authority Criteria

August 21, 2017

New Special Authority criteria From 1 July 2022, funded access to the eight funded MS treatments will be amended in Section B (the Community) of the Pharmaceutical Schedule. Equivalent changes will also be made in Part II of Section H […]